Nursing Elites

1. Which of the following would the nurse expect to see in a client experiencing hypoventilation?

• A. Increased oxygenation in the alveoli
• B. Increased carbon dioxide in the bloodstream
• C. Decreased hemoglobin in the bloodstream
• D. Decreased carbon dioxide in the alveoli

Correct answer: B

Rationale: In hypoventilation, there is inadequate ventilation leading to decreased removal of carbon dioxide. This results in increased carbon dioxide in the bloodstream. The other choices are incorrect because hypoventilation does not improve oxygenation in the alveoli (Choice A), decrease hemoglobin in the bloodstream (Choice C), or decrease carbon dioxide in the alveoli (Choice D).

2. A patient with an 18 pack per year history presents to a family practice clinic complaining of painless hoarseness and inability to clear mucus. A biopsy of respiratory tract cells is taken and shows that these cells have been replaced by less mature squamous epithelium cells. The nurse knows this type of change is referred to as:

• A. Dysplasia
• B. Metaplasia
• C. Hyperplasia
• D. Coagulation

Correct answer: B

Rationale: Metaplasia is the replacement of one type of cell with another, which can occur in response to chronic irritation, such as from smoking. In this case, the respiratory tract cells being replaced by less mature squamous epithelium cells indicate metaplasia. Dysplasia refers to abnormal development or growth of cells, not replacement; hyperplasia is an increase in the number of cells, not a replacement; and coagulation is a process related to blood clotting, not cell replacement.

3. A patient with a history of breast cancer is being prescribed tamoxifen (Nolvadex). What should the nurse include in the patient education about the use of this medication?

• A. Tamoxifen may increase the risk of venous thromboembolism, so the patient should be aware of the signs and symptoms of blood clots.
• B. Tamoxifen may cause hot flashes, so the patient should be prepared for this side effect.
• C. Tamoxifen may decrease the risk of osteoporosis, so the patient should ensure adequate calcium intake.
• D. Tamoxifen may cause weight gain, so the patient should monitor their diet and exercise regularly.

Correct answer: A

Rationale: The correct answer is A. Tamoxifen is known to increase the risk of venous thromboembolism, a serious side effect. Patients should be educated about the signs and symptoms of blood clots, such as swelling, pain, or redness in the affected limb, and the importance of seeking immediate medical attention if they occur. Choice B is incorrect because hot flashes are a common side effect of tamoxifen but not a critical concern like venous thromboembolism. Choice C is incorrect as tamoxifen is not associated with a decreased risk of osteoporosis. Choice D is incorrect because while weight gain can occur with tamoxifen, it is not as crucial to educate the patient about as the risk of venous thromboembolism.

4. Which of the following hormones helps to raise the blood sugar level to help maintain homeostasis?

• A. Antidiuretic hormone (ADH)
• B. Insulin
• C. Glucagon
• D. Thyroxine

Correct answer: C

Rationale: The correct answer is C, Glucagon. Glucagon helps raise blood sugar levels by stimulating the liver to release stored glucose into the bloodstream, thus aiding in maintaining homeostasis. Antidiuretic hormone (ADH), choice A, functions in regulating water balance in the body, not blood sugar levels. Insulin, choice B, lowers blood sugar levels by facilitating glucose uptake by cells. Thyroxine, choice D, is a hormone produced by the thyroid gland that regulates metabolism and has no direct effect on blood sugar levels.

5. A hospital patient's complex medical history includes a recent diagnosis of kidney cancer. Which of the following medications is used to treat metastatic kidney cancer?

• A. Filgrastim (Neupogen)
• B. Aldesleukin (Proleukin)
• C. Interferon alfa-2b (Intron A)
• D. Darbepoetin alfa (Aranesp)

Correct answer: B

Rationale: The correct answer is B: Aldesleukin (Proleukin). Aldesleukin is a medication used in the treatment of metastatic kidney cancer. It is a recombinant interleukin-2 that works by stimulating the immune system to attack cancer cells. Choice A, Filgrastim, is a medication used to stimulate the production of white blood cells. Choice C, Interferon alfa-2b, is used in the treatment of certain cancers but not specifically metastatic kidney cancer. Choice D, Darbepoetin alfa, is used to treat anemia by stimulating red blood cell production and is not indicated for metastatic kidney cancer.

Similar Questions